PS
ADMA icon

Principal Securities’s ADMA Biologics ADMA Stock Holding History

Principal Securities’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-41
Closed -$601 – 1377
2025
Q3 		$601 Hold
41
– – ﹤0.01% 3509
2025
Q2 		$747 Buy
41
+19
+86% +$387 ﹤0.01% 3399
2025
Q1 		$377 Hold
22
– – ﹤0.01% 3399
2024
Q4 		$377 Hold
22
– – ﹤0.01% 3394
2024
Q3 		$440 Buy
+22
New +$342 ﹤0.01% 3297

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Principal Securities's ADMA Position: Q4 2025 in Review

Principal Securities sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 41 shares — an estimated $601 sold.

Principal Securities first reported a position in ADMA in Q3 2024 and held it in 5 quarters. The position peaked at $747 in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • Principal Securities reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 41 ADMA Biologics shares in Q4 2025, an estimated $601.
  • Principal Securities first reported a position in ADMA Biologics in Q3 2024 and held it in 5 quarters.
  • Principal Securities's ADMA Biologics position peaked at $747 in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.